Evidence map›Paper›PMID 23541673›Full record

ArticleBioorganic & medicinal chemistry letters2013

A potential rhodium cancer therapy: studies of a cytotoxic organorhodium(I) complex that binds DNA.

Jeanette R McConnell, Dimple P Rananaware, Deborah M Ramsey, Kai N Buys, Marcus L Cole, Shelli R McAlpine

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Unveiling Luminescent IrChemistry (Weinheim an der Bergstrasse, Germany) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jeanette R McConnellDepartment of Chemistry, University of New South Wales, Kensington, NSW 2052, Australia.
Dimple P Rananaware
Deborah M Ramsey
Kai N Buys
Marcus L Cole
Shelli R McAlpine

Funding

Minority Health &Health Disparities International Research Training ProgramT37MD001442 · NIMHD · SAN DIEGO STATE UNIVERSITY · PI PLEMMONS, DENA · 2005 to 2018
$3.3M
Conformational based design and development of antitumor agentsR01CA137873 · NCI · UNIVERSITY OF NEW SOUTH WALES · PI MCALPINE, SHELLI R · 2009 to 2012
$1.3M
MINORITY INTERNATIONAL RESEARCH TRAINING PROGRAM (MIRT)T37TW000067 · FIC · SAN DIEGO STATE UNIVERSITY · PI POZOS, ROBERT S · 1995 to 2004
$1.2M
FIC NIH HHS T37 TW000067NCI NIH HHS R01 CA137873NIMHD NIH HHS T37 MD001442
6 · The paper itself

Abstract

Described is a novel organorhodium(I) complex that is cytotoxic to the colon cancer cell line HCT116 and alters cell migration, DNA replication, and DNA condensation. Most importantly, the mechanism observed is not seen for the parent organorhodium dimer complex [{RhCl(COD)}2], RhCl3, or the free ligand/proligands (COD and 1-(n)butyl-3-methylimidazolium chloride). Thus, the activity of this organorhodium complex is attributable to its unique structure.

Indexed as

Antineoplastic AgentsCell MovementCisplatinCoordination ComplexesDNADNA ReplicationG1 Phase Cell Cycle CheckpointsHCT116 CellsHumansRhodiumAntineoplastic AgentsCisplatinCoordination ComplexesDNARhodium

Identifiers

PMID23541673
PMCPMC3735625

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.